Board Changes

RNS Number : 0002U

Nuformix PLC

28 July 2022

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU WHICH IS PART OF DOMESTIC UK LAW PURSUANT TO THE MARKET ABUSE (AMENDMENT) (EU EXIT) REGULATIONS (SI 2019/310) ("UK MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION (AS DEFINED IN UK MAR) IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

28 July 2022

Nuformix plc

("Nuformix" or the "Company" or the "Group")

Board Changes

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce the appointment of Dr Daniel ("Dan") Gooding as an Executive Director of the Company with effect from 1 August 2022.

Dr Gooding was a co-founder of Nuformix and the Company's CEO until June 2020.  He instigated the Company's NXP002 programme as an inhaled therapy for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and has been acting as a consultant to the Company since March 2022.  He has over 22 years' experience in commercialisation and business development within the pharmaceutical industry, having received his PhD in chemistry from Leeds University.  Dan began his career in commercial roles with pharmaceutical excipients companies including FMC and Dow Corning.  At Accelrys Ltd, Dan was responsible for sales across the UK and Southern Europe, leading business development within the emerging nanotechnology, drug delivery and formulation sectors, achieving licensing deals with Johnson & Johnson and AstraZeneca.  Since June 2020, Dan has remained close to the fields of fibrosis, oncology and drug repurposing.  Dan supported the management team of Qureight Limited in securing funding and establishing this Cambridge-based start-up, which develops AI-based image processing methods in measuring disease progression and drug response for patients with fibrotic lung diseases including IPF.  Dan has also cofounded TRx Biosciences, a company developing new oral therapies using a novel targeted delivery technology to improve treatment of various cancers and CNS diseases.

In addition, Dr Julian Gilbert, currently a Non-executive Director of the Company has been appointed to the role of Non-executive Chairman.  Following these changes the board of the Company will comprise Dr Julian Gilbert, Non-executive Chairman, Dr Dan Gooding, Executive Director, and Maddy Kennedy, Non-executive Director.

Other than as set out in this announcement there are no further disclosures required in respect of Dr Daniel John Gooding under paragraph 9.6.13 of the Listing Rules.

Commenting, Dr Julian Gilbert, Non-executive Chairman of Nuformix, said: "I am pleased that Dan has agreed to join the board as an Executive Director.  He brings significant history with Nuformix and experience to the table which will help facilitate the progression of our assets, and in particular our NXP002 programme.  I believe that we now have a board and management structure appropriate for the Company's needs in order to optimise value from its assets while maintaining tight control of costs.  I look forward to providing further updates in due course as we progress."

Enquiries:

Nuformix plc
Dr Julian Gilbert, Non-executive Chairman	Via IFC Advisory
Stanford Capital Partners Limited
Tom Price / Patrick Claridge (Corporate Finance)	[phone]
John Howes (Corporate Broking)	[phone]
IFC Advisory Limited
Tim Metcalfe Zach Cohen	[phone] [e-mail]

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of preclinical assets with potential for significant value and early licensing opportunities.

 

END

 

 

BOABDLLLLDLBBBX